Marijuana Use and Health Outcomes in Persons Living with HIV: Protocol for the Marijuana Associated Planning and Long-term Effects (MAPLE) Longitudinal Cohort Study Article

Algarin, AB, Plazarte, GN, Sovich, KR et al. (2022). Marijuana Use and Health Outcomes in Persons Living with HIV: Protocol for the Marijuana Associated Planning and Long-term Effects (MAPLE) Longitudinal Cohort Study . 11(8), 10.2196/37153

cited authors

  • Algarin, AB; Plazarte, GN; Sovich, KR; Seeger, SD; Li, Y; Cohen, RA; Striley, CW; Goldberger, BA; Wang, Y; Somboonwit, C; Ibañez, GE; Spencer, EC; Cook, RL

authors

abstract

  • Background: Marijuana use is common in persons with HIV, but there is limited evidence of its relationship with potential health benefits or harms. Objective: The Marijuana Associated Planning and Long-term Effects (MAPLE) study was designed to evaluate the impact of marijuana use on HIV-related health outcomes, cognitive function, and systemic inflammation. Methods: The MAPLE study is a longitudinal cohort study of participants living with HIV who were recruited from 3 locations in Florida and were either current marijuana users or never regular marijuana users. At enrollment, participants completed questionnaires that included detailed marijuana use assessments, underwent interviewer-administered neurocognitive assessments, and provided blood and urine samples. Ongoing follow-ups included brief telephone assessments (every 3 months), detailed questionnaires (annually), repeated blood and urine samples (2 years), and linkage to medical records and statewide HIV surveillance data. Supplemental measures related to intracellular RNA, COVID-19, Alzheimer disease, and the gut microbiome were added after study initiation. Results: The MAPLE study completed enrollment of 333 persons between 2018 and 2021. The majority of participants in the sample were ≥50 years of age (200/333, 60.1%), male (181/333, 54.4%), cisgender men (173/329, 52.6%), non-Hispanic Black (221/333, 66.4%), and self-reported marijuana users (260/333, 78.1%). Participant follow-up was completed in 2022, with annual updates to HIV surveillance data through at least 2027. Conclusions: The MAPLE study is the largest cohort specifically designed to understand the use of marijuana and its effects on HIV-related outcomes. The study population has significant diversity across age, sex, gender, and race. The data will help clinicians and public health officials to better understand patterns of marijuana use associated with both positive and negative health outcomes, and may inform recommendations for future clinical trials related to medical marijuana and HIV.

publication date

  • August 1, 2022

Digital Object Identifier (DOI)

volume

  • 11

issue

  • 8